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Abstract
Introduction: Equine asthma represents a naturally occurring animal model for
human allergic neutrophilic asthma. Inhalative nanoparticle‐bound cytosine‐
phosphate‐guanosine (CpG‐GNP) immunotherapy, independent of specific allergens,
has already shown promising clinical and immunological results in previous studies
and offers the possibility to treat the underlying cause of the disease. This study
analyses the relationship between dose and response, and evaluates a possible long‐
term effect.
Methods: In the prospective, randomised, double‐blind clinical field study, 29 horses
suffering from equine asthma received 10 inhalation treatments with either 187.5 µg
CpG‐GNP (CpG single dose [CpGsd]; n= 11), 375 µg CpG‐GNP double dose (CpG
double dose [CpGdd]; n= 9) (q48h for 20 days) or 1600 µg beclomethasone (n= 9)
(q24h for 10 days). Each horse was examined three times: before the treatment (I),
immediately after the 10 inhalations (II), and 8 weeks after the final inhalation (III).
The three groups were compared according to clinical and laboratory parameters.
The study examined the sustainability of the long‐term effect of the treatment after 8
weeks, as well as the tolerability of the formula as a double dose.
Results: The CpGsd resulted in a significant improvement in 82% of the
parameters, the CpGdd in 72%. In the long‐term evaluation, the CpGsd showed a
significant improvement in 100% of the parameters in comparison to the initial
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values, the CpGdd in 67%. On the immunological level, the bronchoalveolar
lavage revealed a significant reduction of IL‐4, IL‐8, and interferon‐γ.
Conclusion: Both CpG groups displayed significant improvements in
clinical and laboratory parameters, especially regarding the long‐term effect
of CpGsd. Doubling the CpG dose did not result in any improvement in
comparison to the original single dose. On the immunological level, an anti‐
inflammatory, as well as an immunomodulatory effect, apart from a Th2‐
dominated immune response, could be observed. This immunomodulatory
inhalation treatment could indicate a new possibility for human allergic
asthma therapy.
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1 | INTRODUCTION
Equine asthma (recurrent airway obstruction, heaves) is
one of the most significant chronic inflammatory allergic
diseases of the respiratory tract in horses, and can affect
about 15% or even higher numbers of mature horses kept
in stables.1,2
Equine asthma refers to a multifactorial disease.3 The
main causes are found in the management of the horses
affected, which is why equine asthma may also be
described as a disease of domestication.4
There are over 50 different types of allergens found in
hay and straw dust.5 Mould spores, such as Aspergillus
fumigatus or Faenia rectivirgula, have an especially high
allergen potential. However, storage mites, such as
Lepidoglyphus destructor, and bacterial endotoxins are
also potential trigger factors. Further factors also
contribute, such as inorganic dusts (eg, silicates), cold
and dry air, as well as irritant gases (eg, ammonia).5,6
Besides the environmental factors, a genetic predis-
position also plays an important role.7 A polygenetic
cause for the heredity of equine asthma is considered
highly probable.8
The recurring restriction of the airways is caused on the
one hand by the reversible pathomechanisms bronchospasm,
dys‐ and hypercrinia and the migration of neutrophilic
granulocytes, and on the other hand by the irreversible
remodelling processes in the airways (“airway remodelling”)
with smooth muscle proliferation.6 Exposure to allergens
irritating the mucus membranes results in a constriction of
the bronchi ca. 3 to 5 hours after exposure.9
The inflammation of the airways within the lumen is
primarily due to neutrophilic granulocytes, while lympho-
cytes, mastocytes, plasma cells are located submucosally.10,11
The neutrophils can release mediators, such as elastase, free
oxygen radicals and leukotriene B4, which leads to tissue
damage. In addition, the hypersecretion of the glands in the
airways initiates an increased mucus production with an
altered composition of the mucus.6
As a result, the reduction of the lung volume cannot
be entirely reversed, even with the administration of
bronchodilators.6,12 Furthermore, it can result in both
alveolar ventilation disorders as well as perfusion
disorders, due to a ventilation/perfusion mismatch.6
The allergen‐independent immunotherapy is a promising
treatment method, by which regulatory T cells (Treg) are
activated and the correct T helper (Th) cell balance can be
restored.13 Nanoparticulate cytosine‐phosphate‐guanosine
oligodeoxynucleotides (CpG‐ODNs, CpG‐GNP), through
pathogen‐associated molecular patterns recognized by toll‐
like receptors, were used as immunomodulators in both
human and equine asthma,14-16 and stimulate T helper
subsets with a Th2/Th1 switch and activation of Treg.17 In
equine lungs, macrophages, epithelial cells, capillary en-
dothelial cells, and neutrophilic granulocytes were proven to
be positive for TLR‐9.18
Gelatine nanoparticles (GNP) are biodegradable and
immunologically inert, and are a safe and effective carrier
system for the CpG inhalation.19,20
The aims of this dose‐response study were to compare
two different dosages of the CpG‐GNP inhalation therapy
and to examine its clinical efficacy and to evaluate a
possible long‐term effect over 8 weeks. The results were
compared to a once daily corticosteroid inhalation treat-
ment. The hypothesis was that the immunmodulatory CpG
treatment has an ongoing long‐term effect over 8 weeks
without further medication or management strategies in a
natural environment.
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2 | METHODS
2.1 | Study design and patients
In total, 29 horses with equine asthma participated in the
prospective, randomized, double‐blind clinical field study.
The mean age was 19 (±4.7) years old, 20 males and 9
females, with 11 different breeds, while 15 of the patients
were held in open stables, 13 in stables that opened to the
outside, and 1 in an entirely internal stable (bedding
material: 18 horses with straw, 4 horses with wood
shavings, 2 horses with sawdust, 4 horses without bedding
material; food: 15 horses got dry hay, 11 horses soaked or
steamed hay and 3 horses haylage). Horses were randomly
distributed to the three groups according to age, housing
(contact to hay and straw), and breed (ponies vs horses) to
ensure uniform distribution, beclomethason group: 17.9
(±4.0) years; CpG single dose (CpGsd) group: 20.1 (±3.0)
years; and CpG double dose (CpGdd) group: 19.0 (±6.8)
years). No provocation via contact to hay and straw was
performed before or during the study. Familiar housing
was not changed during the entire study.
The study was approved by the regional legal agency
for animal experiments of the Government of Upper
Bavaria, Germany (No. 55.2‐1‐54‐2532‐207‐13). All of the
horse owners signed an informed consent. The study was
performed in accordance to the guidelines for animal
studies (ARRIVE) and clinical trials (CONSORT).
2.2 | Inclusion criteria
The following inclusion criteria were chosen: upon contact to
dusty hay and straw increased respiratory rate at rest (>16/
minute); an increased abdominal breathing effort; patholo-
gical findings in the lung auscultation; increased percentages
of neutrophilic granulocytes in the airways via bronchoal-
veolar lavage (BAL) (>25%); reduced arterial blood gas levels
at rest (partial oxygen pressure <90mmHg); increased
interpleural pressure (>15 cmH2O); clinical symptoms trig-
gered by contact to hay and straw; and reduction of the
symptoms upon keeping the horses outside.6 Due to the
heterogeneous group of horses (different barns, different
stages of disease and duration of disease) and the character of
the study as a field study the starting point of all horses could
not be exactly the same. Other causes of respiratory disease
were ruled out via the lack of signs of infection and fever,
chronicity, reversibility of signs via avoidance of contact to
trigger factors. Initially 36 horses were included into the
study. Five horses had to be excluded at the beginning
because they were in remission and two dropped out during
the study due to the administration of medications
(nonsteroidal anti‐inflammatory drugs [NSAID] or corticos-
teroids) unrelated to the study to treat lameness causing the
uneven distribution of the sample size of the three treatment
groups CpGsd (n= 11), CpGdd (n= 9), and beclomethasone
(n= 9). All of the horses remained in their own stables
during the entire study, and continued to receive their
familiar management and feed. There were no attempts to
improve the stabling or management of the patients during
this time. The horses of all three groups were treated in
parallel, to limit the effects of seasonal or weather‐related
influencing factors on the results. The study was performed
between April and August. None of the horses received
additional medication within 8 weeks previous to the study
or during the study itself.
2.3 | Intervention
GNPs were produced and loaded with CpG‐ODN 2216
(Biomers GmbH, Ulm, Germany) as described pre-
viously.15,16,21 For the CpG‐GNP single dose, each inhala-
tion utilized 187.5 μg CpG‐ODN, bound to 3.75mg GNP
and dispersed in 2.5mL highly purified water (HPW), with
a final concentration of 1.5mg/mL GNP and 0.075mg/mL
CpG‐ODN as described previously.15,16,22 For the CpG‐GNP
double dose, each inhalation utilized 375 μg CpG‐ODN,
bound to 7.5mg GNP and dispersed in 5mL HPW with a
final concentration of 1.5mg/mL GNP and 0.075mg/mL
CpG‐ODN. All inhalation treatments (CpG and beclo-
methasone) were administered via the Equine Haler
(Equine HealthCare Aps, Hoersholm, Denmark) combined
with the Aeroneb Go micropump nebulizer (Aerogen,
Galway, Ireland) as described previously.15,16
The 10 CpG‐GNP inhalations were administered to each
horse every 2 days, in accordance with the protocol from the
preceding studies for altogether 20 days. The 48 hour interval
between inhalations was chosen according to the in vivo
stability of CpG‐ODN shown to be 48 hours23 and the reliable
protocol.15,16 The beclomethasone group (Sanasthmax 400
Mikrogramm/ 1mL, Chiesi GmbH, Hamburg) received once
daily inhalations (every 24 hours) of 1600 µg (4mL), on 10
consecutive days.24 The q24h interval for beclomethasone
treatment was chosen instead of a q12h interval because of
no feasibility of this field study. The inhalations were
administered by two people (CB, SG). Both clinical and
laboratory examinations were blind.
2.4 | Clinical and laboratory evaluations
The first examination of the horses was completed before
treatment (I) and included a thorough clinical examination
(auscultation, respiratory rate and type, nasal discharge,
provocation test, and lung percussion), an evaluation of the
pulmonary function parameters (interpleural pressure,
arterial blood gas values), a bronchoscopy with evaluation
of the amount of mucus in the airways, as well as a BAL. In
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addition, immunological parameters (detailed below) were
determined from the BAL. The second examination (II)
was conducted directly after the 10 inhalations, either after
3 weeks (for the CpG‐GNP treatment) or after 10 days (for
the beclomethasone treatment). The third examination (III)
was conducted 8 weeks after the last inhalation treatment.
The clinical examination was conducted as described
previously15,16,22 and in accordance with established and
standardized scoring systems5,25,26 (Supporting Information).
All of the horses were observed clinically on a daily
base by the owners and CB and SG during inhalation
treatment, and completely with endoscopy, interpleural
pressure measurement, blood gas analysis, and blood
work during the three examination points to determine
the tolerability of the dosage and the treatment regimen.
This observation recorded any nasal discharge (consis-
tency and quality), cough (at rest and during exertion),
signs of bronchospasm (wheezing and whistling, nasal
flaring, and increased abdominal breathing effort),
increased respiratory rate at rest, visible redness or
swelling of the mucous membranes within the scope of
the endoscopic examination, follicular hyperplasia, and/
or decreased blood gas values. In addition, the rectal
temperature was measured daily and a white blood cell
count, a differential blood count and a fibrinogen test
were evaluated within the scope of the three control
examinations for signs of adverse systemic effects.
BAL was performed with 250mL of sterile saline. BAL
was centrifuged (300 g for 6 minutes) and the supernatant
was immediately frozen with liquid nitrogen and stored
at −80°C until the samples were evaluated. The cell
suspension was placed on ice during transportation.
2.5 | Cytokine assay
The analysis of the cytokines IL‐4, IL‐10, IL‐17, and
interferon‐γ from BAL supernatant was conducted in the
Cornell Animal Health Diagnostic Center (Cornell Univer-
sity, Ithaca, NY) via the Multiplex Assay27 (Supporting
Information). For this purpose, the samples were sent frozen
on dry ice (TNT, Germany).
2.6 | Magnetic‐activated cell sorting
The BAL cell suspensions were stored on ice immediately
after extraction and were processed in the laboratory within a
maximum of 3 hours.
Following this, the samples were centrifuged for
10 minutes at 300 g.
To free the samples from mucus as much as possible,
the BAL was filtered through a single layer of sterile gauze.
Subsequently, 50 µL of the cell suspension was extracted
and mixed with 50 µL of trypan blue (live/dead staining)
and the percentage of living cells were determined under
the microscope.28
The positive selection of CD4+ T lymphocytes occurred
in accordance with the magnetic‐activated cell sorting
(MACS)‐ protocols of the company Miltenyi Biotec.29,30
The purity of the CD4+ cells was monitored via flow
cytometry (FACS‐Gerät: MACSQuant VYB; Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) following the MACS
separation (Figures S4‐S6). These checks were carried out
randomly and were already tested in the preliminary stages
of the execution of the study. For this purpose, a fluorescein
isothiocyanate (FITC) staining dye was utilized, coupled to a
CD4+ antibody (FITC‐conjugated Goat antimouse IgG
antibody; Miltenyi Biotec GmbH), to test the purity of the
fractionation.28 In this way, the successful selection of CD4+
could be determined at 98% (Figure S6).
2.7 | Messenger RNA assay
The quantitative analysis of the messenger RNA (mRNA)
from the CD4+ lymphocytes selected via MACS was
conducted in the Gluck Center, KY via Real Time PCR.
To this end, the samples were sent via a cooled transport
(Medpak Thermo, TNT, Troisdorf).
This analysis determined the mRNA of the transcription
factors Forkhead Box Protein P3 (FoxP3), T‐bet (Th‐1‐specific
T‐box transcription factor), GATA‐3 (Trans‐acting T‐cell‐
specific transcription factor) and the cytokines IL‐8 and
TGF‐β (transforming growth factor‐β).30-32
The isolation of the mRNA was conducted according to
a fixed schema (Supporting Information).33 The results
were mathematically adjusted with the help of a reference
gene (BGus).30 For the final results, the logarithmic value
of relative quantification was determined for each of the
parameters examined.
2.8 | Statistical analysis
The statistical analysis of the results utilized the GraphPad
Prism 5 Software (Graphpad Software Inc., La Jolla, CA). The
follow‐up examinations within the treatment groups (be-
tween the first and second, and between the first and third
examinations) utilised the Wilcoxon matched‐pairs test for
nonparametric data. The comparison between the groups
was conducted with the Mann Whitney Test (beclometha-
sone with CpGsd or CpGdd) with adjustment according to
Bonferroni for multiple tests. Both were performed one‐
tailed. In addition, the effect size (Cohen's d) of each
treatment on the parameters examined was determined
(large clinical effect: d>0.8; medium effect: 0.5‐0.8; small
effect: 0.2‐0.5). The calculation of the effect size was
performed using the EffectSize Calculator (http://davidmla-
ne.com/hyperstat/effect_size.htm, Robert Coe).34 Sample size
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calculation was performed with 12 subjects per group (one‐
tailed, Cohen's d>1 for relevant clinical effect with a power
of >0.8 and α P=0.05).
3 | RESULTS
3.1 | Adverse effects
During the entire study, no clinical or clinical‐pathological
indications of local or systemic side effects could be
determined as the result of any of the inhalation treatment.
Two horses dropped out during the study due to the
administration of medications (NSAID or corticosteroids)
unrelated to the study to treat lameness.
3.2 | Respiratory rate at rest
Only the two CpG groups showed a significant improvement
in the respiratory rate directly after treatment (Table 1;
Figure 1). This effect was also still evident after 8 weeks. The
beclomethasone group did not show any improvement.
In the comparison of the three treatment groups, the
CpGsd could significantly improve the respiratory rate
directly after treatment, in comparison to the beclometha-
sone therapy (Table S3). A significant improvement in the
respiration rate was also determined after 8 weeks, both in
the CpGsd and in the CpGdd, in comparison to the
beclomethasone group (Table S3).
There was no significant difference determined
between the two CpG treatment groups, neither between
I and II, nor regarding the long‐term effect (III).
The comparison between the group of all horses treated
with CpG and the beclomethasone group revealed a
significant difference on the side of the CpG therapy, both
between I and II, as well as between I and III (Table 2).
3.3 | Breathing type
All three therapy regimens resulted in a significant
improvement in the breathing type both directly after
treatment, as well as after 8 weeks (Table 1; Figure 1).
The CpGdd showed the smallest effect (Table 1).
The comparison of the three treatment groups
determined no significant differences (Table S3).
In the comparison between all horses treated with
CpG and the beclomethasone group, there were no
significant differences observed between either I and II,
or between I and III (Table 2).
3.4 | Nasal flaring
All three treatment groups showed a significant clinical
improvement of nasal flaring, both directly after the
treatment, as well as after 8 weeks (Table 1; Figure 1). The
greatest effects were evident after 8 weeks (Table 1).
The comparison between the three forms of treatment
determined no significant differences (Table S3).
In the comparison between all horses treated with
CpG and the beclomethasone group, there were no
significant differences observed between either I and II,
or between I and III (Table 2).
3.5 | Nasal discharge
All three treatment regimens demonstrated a marked
reduction of nasal discharge both directly after treat-
ment and after 8 weeks (Table 1; Figure 1). Directly
after the treatment, the CpGsd and beclomethasone
groups showed significantly greater effects than the
CpGdd (Table 1). After 8 weeks, the greatest effects and
clinical improvements were demonstrated by the
CpGsd (Table 1).
However, no significant differences were determined in
the comparison of the different forms of therapy (Table S3).
In the comparison of all horses treated with CpG with
the beclomethasone group, there were no significant
differences observed between either I and II, or I and III
(Table 2).
3.6 | Auscultation of the airways
Both CpG groups showed a significant improvement in the
auscultation findings after treatment (Table 1; Figure 1).
After 8 weeks also the beclomethasone group demonstrated
a significant improvement (Table 1).
The comparison of the three treatment forms revealed
no significant difference, except between the CpGdd and
the beclomethasone group after 8 weeks (Table S6).
In the comparison of the long‐term effect of treatment
between all horses treated with CpG and the beclometha-
sone group, a significant improvement in the auscultation
findings was determined in the horses receiving CpG
therapy (Table 2).
3.7 | Partial pressure of oxygen
All three groups showed a significant improvement in the
partial pressure of oxygen both directly after treatment as
well as after 8 weeks (Table 1; Figure 1). There was no
significant difference between the treatment groups
(Table S3).
The comparison between all horses treated with
CpG with the beclomethasone group indicated no
significant difference between I and II or between I
and III (Table 2).
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FIGURE 1 Absolute values of breathing rate (n/minute) and pattern (RU), lung auscultation (RU), interpleural pressure measurement
(cmH2O), oxygen partial pressure (mmHg), AaDO2 (mmHg), percentage of neutrophils in BAL (%), nasal discharge (RU), endoscopic
quantification of secretion (RU) and viscosity (RU) in equine asthma‐affected horses at first examination before inhalation treatment (I),
after 10 inhalations (II) of beclomethasone (n = 9 equine asthma‐affected horses), CpG single dose (CpGsd) group (n = 11 equine asthma‐
affected horses) and CpG double dose (CpGdd) group (n = 9 equine asthma‐affected horses) and after 8 weeks without any treatment to
evaluate long‐term effect (III). Calculated value of P< 0.05 displayed as *, P< 0.01 as **. AaDO2, alveolar‐arterial oxygen gradient; BAL,
bronchoalveolar lavage; RU, relative unit
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3.8 | Alveolar‐arterial oxygen gradient
The beclomethasone and CpGsd group showed a significant
improvement in the alveolar‐arterial oxygen gradient
(AaDO2) directly after treatment, as well as a sustained
effect over 8 weeks including the CpGdd group (Table 1;
Figure 1). In the CpG groups, however, this was a large effect
compared to the beclomethasone group (Table 1).
Between the treatment regimens, no significant difference
was determined (Table S3), except between the beclometha-
sone group and the CpGdd between I and II in favour of the
beclomethasone group.
The comparison of all horses treated with CpG
with the beclomethasone group showed a significant
long‐term effect over 8 weeks with the CpG therapy
(Table 2).
3.9 | Measurement of interpleural
pressure
Both the beclomethasone group as well as the CpGsd
group produced a significant reduction of the interpleural
pressure directly after treatment and after 8 weeks
(Table 1; Figure 1).
The comparison of treatments indicated no significant
advantages to any one treatment form (Table S3).
The comparison of all horses treated with CpG with the
beclomethasone group indicated no significant differences
between I and II or between I and III (Table 2).
3.10 | Amount of tracheal secretion
All three treatment regimens resulted in a significant
reduction of the amount of tracheal secretion (Table 1;
Figure 1). This effect was still clearly evident in both CpG
groups after 8 weeks, with a greater effect than in the
beclomethasone group (Table 1).
The comparison of the different therapy forms
indicated no significant differences (Table S3).
The comparison of all horses treated with CpG with
the beclomethasone therapy revealed no significant
differences among the treatment forms between I and
II and between I and III (Table 2).
TABLE 2 Comparison in percent of all CpG treated horses (single and double dose; n = 20) with beclomethasone treatment (n = 9)
between first and second (I‐II) and first and third examination (I‐III)
Treatments in comparison Examination stage I‐II Examination stage I‐III
Breathing rate Both CpG groups—beclomethasone group P= 0.006 P= 0.004
Breathing type Both CpG groups—beclomethasone group P= 0.903 P= 0.956
Nasal flaring Both CpG groups—beclomethasone group P= 0.216 P= 0.446
Nasal discharge Both CpG groups—beclomethasone group P= 0.458 P= 0.190
Auscultation Both CpG groups—beclomethasone group P= 0.237 P= 0.034
Arterial oxygen pressure Both CpG groups—beclomethasone group P= 0.453 P= 0.190
AaDO2 Both CpG groups—beclomethasone group P= 0.057 P= 0.042
Interpleural pressure Both CpG groups—beclomethasone group P= 0.097 P= 0.447
Tracheal mucus Both CpG groups—beclomethasone group P= 0.500 P= 0.106
Viscosity Both CpG groups—beclomethasone group P= 0.017 P= 0.021
Neutrophils Both CpG groups – beclomethasone group P= 0.327 P= 0.021
HOARSI Both CpG groups—beclomethasone group _ P= 0.007
IL‐4 BAL Both CpG groups—beclomethasone group P= 0.190 P= 0.029
IL‐10 BAL Both CpG groups—beclomethasone group P= 0.167 P= 0.237
IL‐17 BAL Both CpG groups— beclomethasone group P= 0.089 P= 0.174
IFN‐γ BAL Both CpG groups—beclomethasone group P= 0.491 P= 0.343
FoxP3 CD4 BAL Both CpG groups—beclomethasone group P> 0.999 P= 0.257
TGF‐ β CD4 BAL Both CpG groups—beclomethasone group P= 0.491 P= 0.092
T‐BET CD4 BAL Both CpG groups—beclomethasone group P> 0.999 P> 0.999
GATA‐3 CD4 BAL Both CpG groups—beclomethasone group P> 0.999 P> 0.999
IL‐8 CD4 BAL Both CpG groups—beclomethasone group P> 0.999 P= 0.703
Abbreviations: AaDO2, alveolar‐arterial oxygen gradient; BAL, bronchoalveolar lavage; CpG, cytosine‐phosphate‐guanosine; HOARSI, horse owner assessed
respiratory signs index; IL, interleukin.
KLIER ET AL. | 139
3.11 | Viscosity of secretion
Both CpG groups showed a significant improvement in
the viscosity of the tracheal mucus directly after
treatment and sustained over 8 weeks (Table 1; Figure
1). The beclomethasone group showed no improvement
(Table 1; Figure 1).
The comparison of the different therapy forms
indicated no significant difference (Table S3).
The comparison of all horses treated with CpG with
the beclomethasone group revealed a significant differ-
ence on the part of the CpG treatment between I and II
and between I and III (Table 2).
3.12 | Neutrophilic granulocytes in the
BAL
All three treatment forms resulted in a significant
reduction in the neutrophilic granulocytes in the BAL
directly after treatment (Table 1; Figure 1). Furthermore,
the CpG groups also showed a significant improvement
after 8 weeks in contrast to the beclomethasone group
(Table 1; Figure 1).
The comparison of the three therapy forms showed no
significant differences (Table S3).
The comparison of all horses treated with CpG and the
beclomethasone group revealed a significant difference on
the part of the CpG therapy after 8 weeks (Table 2).
3.13 | HOARSI
Both CpG groups attained a significant improvement in
more than half of the HOARSI scores after 8 weeks (Table
1; Figure 1). This was also reflected in the large effect size
(Table 1).
The comparison between CpG and beclomethasone
treatment revealed a significant improvement on the side
of the CpG therapy in its long‐term effect (Table S3). There
was no significant difference determined between the two
CpG groups.
The comparison of all horses treated with CpG and
the beclomethasone group showed a significant differ-
ence in favour of the CpG treatment (Table 2).
3.14 | Laboratory diagnostic parameters
There were no significant differences among the therapy
groups in any of the cytokines examined (IL‐4, IL‐10, IL‐17,
and interferon‐gamma [IFN‐γ]) (Table S3). The comparison
between all horses treated with CpG with the beclometha-
sone group demonstrated no significant difference neither
between I and II, nor between I and III for any of the
cytokines examined.
IL‐4 decreased significantly in the CpGsd and
beclomethasone group directly after treatment and after
8 weeks (Table 1; Figure 2). The beclomethasone group
showed the greatest effect here (Table 1).
FIGURE 2 IL‐4 (pg/mL), IL‐10 (pg/
mL), IL‐17 (U/mL), and IFN‐γ (U/mL)
concentration in BAL samples of equine
asthma‐affected horses at first examination
before inhalation treatment (I), after 10
inhalations (II) of beclomethasonee
(n= 9 equine asthma‐affected horses),
CpG single dose (CpGsd) (n= 11 equine
asthma‐affected horses) or CpG double dose
(CpGdd) (n=9 equine asthma‐affected
horses) and after 8 weeks without any
treatment to evaluate long‐term effect (III).
Calculated value of P<0.05 displayed as
*, P<0.01 as **. BAL, bronchoalveolar
lavage; IFN‐γ,
interferon‐gamma; IL, interleukin
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IL‐10 decreased in both CpG groups directly after
treatment (Table 1; Figure 2). After 8 weeks, the CpGdd
group showed a 100% increase (Table 1). The beclometha-
sone group showed an increase of 25% directly after
treatment and after 8 weeks (Table 1).
IL‐17 increased by 50% in the beclomethasone group
directly after treatment (Table 1). The CpGsd showed a
decrease, and the CpGdd showed nearly no change
(Table 1; Figure 2). After 8 weeks, both CpG groups
displayed a decrease by approximately 70%, while the
beclomethasone group showed a slight increase in
comparison to the original value (Table 1).
IFN‐γ showed a minimal decrease in all three groups
directly after treatment (Table 1). This was also evident in
both CpG groups after 8 weeks (Table 1). The beclometha-
sone group returned to the original value after 8 weeks
(Table 1: Figure 2).
3.15 | Results of the mRNA analysis
from CD4+ lymphocytes
The results of the mRNA analysis (FoxP3, TGF‐β, T‐bet,
GATA‐3; IL‐8) from the CD4+ lymphocytes of the BAL are
portrayed in Figure 3 and Table 1. The comparison of
treatments indicated no significant differences among the
treatment forms, except in T‐bet between I and II between
CpGsd and CpGdd (Table S3). There were also no
significant differences between all horses treated with
CpG and the beclomethasone group in the parameters
examined (Table 2).
FIGURE 3 FoxP3, TGF‐β, T‐bet,
GATA3, IL‐8 m‐RNA concentration via
real‐time PCR from CD4+ cells in BAL
samples of equine asthma‐affected horses.
The values refer to a reference gene
(BGus), which was used for calibration.
For calculation, the logarithm of the
relative quantification (lnRQ values) was
used. First examination before inhalation
treatment (I), second examination (II)
after ten inhalations of beclomethasone
(n = 9 equine asthma‐affected horses),
CpG single dose (CpGsd) (n = 11 equine
asthma‐affected horses) or CpG double
dose (CpGdd) (n = 9 equine asthma‐
affected horses) and third examination
(III) after eight weeks without any
treatment to evaluate long‐term effect.
Calculated value of p< 0.05 displayed
as *
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FoxP3 decreased significantly after 8 weeks in CpGsd
group (Table 1; Figure 3). The beclomethasone group
showed a significant increase after 8 weeks (Table 1;
Figure 3). The CpGsd showed a significant decrease of
FoxP3 after 8 weeks (Table 1; Figure 3).
TGF‐β decreased minimally in all three groups
directly after treatment (Table 1; Figure 3). After 8
weeks, the values of all three groups were close to the
original values (Table 1; Figure 3).
The beclomethasone group showed a minimal in-
crease at the second and third examinations in T‐bet
expression (Table 1; Figure 3). Both CpG groups showed
a decrease in T‐bet after 8 weeks, which was significant
in CpGsd (Table 1; Figure 3).
GATA‐3 decreased minimally but not significant in both
CpG groups directly after treatment and after 8 weeks (Table
1; Figure 3). The beclomethasone group showed an increase,
which was significant after 8 weeks (Table 1; Figure 3).
IL‐8 decreased minimally in both CpG groups directly
after treatment (Table 1; Figure 3). After 8 weeks, both
CpG groups showed a significant decrease (Figure 3).
4 | DISCUSSION
The current study aimed to compare two different dosages of
the CpG‐GNP inhalation therapy, to examine its efficacy and
to evaluate a possible long‐term effect over 8 weeks. The
results were compared to a once daily corticosteroid
inhalation treatment. The hypothesis was that the immun-
modulatory CpG treatment has an ongoing long‐term effect
over 8 weeks without further medication or management
strategies in a natural environment. This was fulfilled. The
dose‐response comparison of the CpGsd (single dose) and
the CpGdd (double dose) enabled the next step in the
direction of dose‐finding (Phase IIb), after reviewing the
therapy concept (Phase IIa) of a previous study.16 The double
CpG dose showed no significant advantages over the single
CpG dose in the majority of the parameters examined.
Therefore, doubling the dosage seems neither necessary nor
advisable. The loss of effect for some parameters when
doubling the dose of CpG could be a result of local saturation
level. In mice higher dosages per kg body weight were used
via i.v. injection (50 µg per mouse)19 which indicate in our
understanding that this is not a detrimental effect of the drug
or the vehicle at high dose. Furthermore, the study aimed to
evaluate the immunological effects of the Th‐1 and Th‐2
immune response, as well as the regulatory T cells. In
human medicine, CpG administration has been shown to
reduce Th2 immune response and activate T regulatory
cells.35 On the immunological level, a significant decrease of
the Th2 cytokine IL‐4 and the Th1 cytokine IFN‐γ was
indicated. The mRNA analysis showed that the CpG therapy
resulted in a decrease of IL‐8, T‐bet, and GATA‐3‐mRNA
expression.
Most preparations of corticosteroid inhalations should
ideally be administered every 12 hours, which is often not
possible for many horse owners.36,37 For economic reasons,
this was also not possible within the scope of this study,
since the horses were located in their home stables and the
inhalations were conducted by the veterinarians (SG, CB),
to ensure that the treatments were conducted properly. In
addition, Niedermaier and Gehlen described a clinical
sufficient effect of once a day inhalation treatment of a
corticosteroid in many patients.36 However, for a better
comparability it would be recommendable to treat all
groups with the same interval. This is the aim for the next
study. The CpG treatment was performed in 48 hour
intervals according to the former protocol.16 The number
of inhalations was the same for both treatment regimens,
and the follow‐up examination was conducted directly
following the final treatment for both groups, to enable an
accurate comparison of the treatments.
Inhalative administration of the medication was chosen,
to reduce potential systemic side effects and use the
advantage of the topical, inhalative administration with its
locally restricted effect and targeted application at the site of
pathogenesis.36,38 The target cells are those with TLR9
receptors, such as pulmonary neutrophils, bronchial epithe-
lial cells, capillary endothelial cells and macrophages.18
GNPs have proven to be a safe and effective carrier
system for the CpG inhalations.15,16,19,20,22 Through varia-
tions in the production of the GNP, the previous production
process could be optimized and designed more efficiently.21
Based on the results of Zillies et al,39 Geh et al also developed
a storage stable and sterilised lyophilisate of the CpG‐GNP
dispersion, which in future will make its storage and
application much easier and more practicable.40
To reduce the effects of seasonal fluctuations on the
therapy effect as much as possible, the patients of all
three treatment regimens were treated in parallel. In this
way, the influence of external conditions on the effect of
the different treatment forms was minimised.
Due to the fact that there are no data supporting a long‐
lasting effect of inhaled corticosteroids in asthmatic horses,41
this means that the observed improvement 8 weeks after the
end of the treatment with beclomethasone could also be due
to other factors (eg, season, weather, hay quality), that are
likely present in the CpG groups and during the treatment
period. No side effects were evident in any of the horses of
the three groups, which would have required the disconti-
nuation of the study. The fibrinogen values measured also
showed no indication of an inflammatory response resulting
from the treatment (data not shown). These results reinforce
the finding gained by the previous studies, that the CpG‐GNP
is well tolerated by the patients.15,16,20
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The CpG therapy provides a new alternative for
horses, which should not be treated with corticoster-
oids42 due to pre‐existing conditions (eg, PPID, equine
metabolic syndrome, laminitis).
The CpG inhalations, in contrast to the corticosteroid
therapy, succeeded in significantly sinking the respira-
tory rate at rest, as well as regarding the long‐term effect.
Since breathing type is an external sign of the restriction
of the airways,42 the improvements in the beclomethasone
and CpGsd groups are of great clinical relevance.
In addition to the breathing type, nasal flaring was
evaluated. Nasal flaring is the result of increased breathing
activity, as well as a mechanism for the reduction of
respiratory resistance.43 All therapy forms attained sig-
nificant improvements, as well as regarding the long‐term
effect. Therefore, in connection with further pulmonary
function tests, a reduction of breathing difficulty and thus
an improvement in general condition can be determined
in the horses treated in all three groups.43
The reduction of nasal discharge in the treatments
agrees with the findings of the endoscopic examination.
The occurrence of mucus nasal discharge, especially when
accompanied by occasional coughing, can be an early
clinical indication for a higher risk of equine asthma,44,45
and can be used as a good indicator for the development of
the disease by the owner or in the clinical examination.46
The partial pressure of oxygen was determined to
evaluate the oxygen supply. In all three forms of
treatment, a significant increase was identified in the
partial pressure of oxygen (PaO2) measurements, and also
after the evaluation of the long‐term effect. The increase in
PaO2 values in connection with reduced levels of
interpleural pressure could be a clear indication of an
improvement of the pulmonary ventilation.6
The PaO2 can be subject to certain variations, depending
on geographical location (elevation over NHN) and weather
influences (high or low pressure), since it is dependent on
the predominant barometric pressure.26 For this reason, in
addition to the PaO2 in connection with the predominant
barometric pressure at the time of the examination, the
alveolar arterial oxygen gradient was also calculated.26 The
arterial partial oxygen pressure, as well as the alveolar
arterial gradient, revealed greater clinically relevant results
from the CpG inhalations than from the established
beclomethasone therapy. The larger improvement is in part
due to the higher baseline values of PaO2 for the
beclomethasone. Since both parameters (PaO2 and AaDO2
gradient) reach a plateau in health, there was less
improvement possible in this group, regardless of the
medication efficacy. In a previous study, no statistically
significant long‐term effect was identified after five inhala-
tions with the single CpG dose.16 However, the current
study showed that increasing the number of inhalations
with CpG‐GNPs to 10 resulted in a positive effect on both
the PaO2, as well as the AaDO2, which was still evident after
8 weeks.
In a previous study, no statistically significant long‐
term effect was identified after five inhalations with the
single CpG dose.16 However, the current study showed
that increasing the number of inhalations with CpG‐GNPs
to 10 resulted in a positive effect on both the PaO2, as well
as the AaDO2, which was still evident after eight weeks.
The measurement of the interpleural pressure gives an
indication of the degree of severity of the current
bronchoconstriction.47 To compensate for the constriction
of the airways and prevent hypercapnia, the interpleural
pressure increases. Therefore, an abdominally‐forced breath-
ing effort becomes necessary during bronchoconstriction, in
which the expiratory pressure is significantly increased, and
the interpleural pressure increases as a result.6 All three
treatment regimens attained a short‐ and long‐term reduc-
tion of the indirectly measured pulmonary pressure.
Improving the interpleural pressure should reduce the
airway resistance with a reduction of the bronchospasm.6
In the entirety of the three treatment groups, the final
mean value for the interpleural pressure was still somewhat
above the physiological range of <10 cmH2O. This could be
associated with the airway remodelling in the lungs, which
occurs especially due to neutrophilic inflammatory reac-
tions, epithelial proliferation, and smooth muscle prolifera-
tion.4,6 These reconstruction processes make a full
regeneration of the tissue very unlikely in a longer‐existing
illness.43 Since 79% of the horses in this study had already
suffered from the disease for 5 years or longer, one must
assume at least partially irreversible lung damage.
Excessive accumulation of mucus in the airways is an
important indicator of equine asthma,25,48 which can be
caused by increased secretion or by reduced mucociliary
clearance.25
All three forms of treatment showed a long and short‐
term reduction of the quantities of mucus, evaluated
endoscopically. In agreement with the results of previous
studies,16 the treatment with CpG reduced the quantity of
mucus, resulting in an improvement of the symptoms
such as mucus‐induced coughing or breathing difficulty,
as these are directly correlated.6,49
In horses that suffer from equine asthma, there is a
high correlation between the accumulation of mucus and
the percentage of neutrophils in the BAL.50 Neutrophilic
inflammation of the airways can cause the increased
production of mucus, due to the increased secretion of
mucines, among other things.50,51 Because a pathological
increase in the quantity of secretion is also caused by
oxidative processes of neutrophilic inflammation,52 a
decrease in the quantity of mucus can also be considered
an anti‐inflammatory effect of the CpG treatment.
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The reduction of the quantity of the mucus also has a
positive influence on the improvement of the partial
oxygen pressure, since a smaller quantity of mucus in the
airways also improves the gas exchange in the lungs.
Besides the quantity of mucus, its viscosity was also
evaluated. In contrast to the therapy with beclomethasone,
a significant reduction of the viscosity of the mucus was
evident after the inhalations with both CpG concentrations.
In clinical exacerbation of equine asthma, the mucus
becomes more viscous,25 so that an improvement of the
viscosity indicates that the therapy could improve muco-
ciliary clearance. Furthermore, the reduction of mucous
secretion can be expected due to the reduced quantity of
mucus from the CpG treatment.25 Herholz et al53 could
also determine a positive correlation between the reduction
of the mucus viscosity and the results of the pulmonary
function tests.
The percentage of neutrophilic granulocytes in the total
cell count of the BAL is evaluated, as the most important
indicator of an inflammation of the lower airways.3,6 The
results indicate that only the CpG therapy can achieve a
significant sustained anti‐inflammatory effect over 8 weeks.
The reduction of pulmonary inflammation is one of the most
important cornerstones in the treatment of equine asthma.3
An increased accumulation of neutrophils in the airways
due, among other things, to oxidative stress, creates an
environment producing increased mucus production and
bronchospasm.6,11 It is already known that treatment with
corticosteroids only decreases the percentage of neutrophils
with concurrent environmental changes and thus can
achieve an improvement in the clinical symptoms.11,54
Therefore, the effect attained by the CpG treatments is of
great importance, since the long‐term effect was actually
significantly superior to that of the beclomethasone therapy,
which was previously considered the most effective form of
medicamentous therapy to manage clinical symptoms of
equine asthma.6,55 The therapy also achieved a long‐term
improvement in the inflammatory status in the lungs.
Accordingly, the percentage of neutrophils continued to
drop off in the 8 weeks following the last treatment with
CpG.
The owners were questioned regarding pathology
and performance before the first treatment and 8 weeks
after the last treatment, via the standardized HOARSI
questionnaire (Horse Owner Assessed Respiratory
Signs Index).56 The beclomethasone therapy resulted
in a minimal reduction of the mean value of the scores.
After the CpG treatments, however, the owners rated
the condition of their horses as significantly improved.
The HOARSI questionnaire is a reliable and informa-
tive assessment of the medical condition of the horse
and the results of the examinations of the respiratory
tract.46,57
Since a predominant Th‐2 immune response, among
others, is responsible for horses with equine asthma
reacting to certain allergens with an exacerbation of the
airway pathology,58 a goal of this study was to show that
the therapy can achieve a reduction of the Th2 cytokine
IL‐4. This was confirmed by the results of the beclometha-
sone and CpGsd group which could achieve a significant
and sustained reduction of the IL‐4 concentration in the
BAL. This agrees with a previous study27 and the results of
a study from Giguere et al54 in which an inhalative
fluticasone therapy could also effect a reduction of the
allergy‐mediated Th2 cytokine. It confirms the capacity of
the CpG treatment to downregulate IL‐4.
IL‐4 is also involved in the recruitment of neutrophils,6,59
which was also decreased in the BAL by the treatments.
Tregs are attributed a critical protective role against
allergies.60 These cells produce the anti‐inflammatory
cytokine IL‐10, which has an important suppressive
influence on the allergy‐mediating Th2 cytokines like
IL‐4 or IL‐5, as well as an inhibitory effect on the
proinflammatory Th1 cytokine IFN‐γ.17,61,62 Neither the
beclomethasone nor the CpG treatments could effect a
significant increase in IL‐10. A slight increase in the CpG
groups, after 8 weeks could possibly indicate a delayed
occurrence of immunomodulation.62
In other studies, an upregulation of the IL‐10
production could be achieved through stimulation with
CpGs in both humans63 and horses.15,20 The majority of
participants in this study were horses of advanced age
(86% were 15 years old or more). Robbin et al60 described
how fewer FoxP3 positive CD4+ cells could be found in
horses of older age.
The Th17 cytokine IL‐17 is attributed a role in the
pathogenesis of equine asthma, due to its chemotactic
and activating effect on neutrophils.64,65 It is assumed
that corticosteroids have an inhibitory effect on Th2
cytokines (IL‐4 and IL‐5) and IL‐8,66 and therefore work
via other mechanisms than the Th17‐mediated path. This
could also explain why the IL‐17 concentration after
treatment increased significantly in the beclomethasone
group in comparison to the CpG groups.
Since an increased expression of IL‐17 in the BAL of
horses with equine asthma after exposure to allergens
was determined in a study from Debrue et al,64 the
nonsignificant decrease in the IL‐17 concentrations in
both CpG groups regarding the long‐term effect can be
considered a positive treatment response. This is con-
trasting to the beclomethasone therapy.
A decrease in the IL‐17 concentration, as was
observed in both CpG groups, could also be associated
with the simultaneously observed reduction of the
neutrophilic granulocytes in the BAL through the CpG
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therapy and therefore a reduction of the inflammation in
the lower airways.65
IFN‐γ is an important representative of the Th1
cytokine.67 IFN‐γ decreased in all three groups direct after
treatment. This was significant only in the CpGsd group.
These results contradict the results determined by Bohle,67
who described an increased release of the Th1 cytokine
IFN‐γ, which should have an inhibitory effect on the Th2
cytokines IL‐4, IL‐5, and IL‐13.68 After 8 weeks only the
CpG groups showed a nonsignificant decrease. This can,
however, be considered a positive result regarding the
sustained reduction of the inflammatory response and
neutrophilic granulocytes in the lungs.
Studies of horses with equine asthma,54 as well as
human asthma sufferers,69 determined increased IFN‐γ
expression in phases of exacerbation. In a study by
Horohov, IFN‐γ mRNA was also increased in equine
asthma exacerbation after antigenic challenge.30 Since
IFN‐γ can contribute to an increase in the chronic
pulmonary inflammation in asthmatic illnesses,69 and, in
combination with IL‐10 and Tregs, can also have an
inhibitory effect on the Th2 immune response,68 the
results attained for IFN‐γ must be considered in relation-
ship to the Tregs and the clinic.70
The measurement of the mRNA in CD4+ cells serves
to examine the influence of the forms of treatment on the
activity of Tregs. In a study from El Abbas et al horses
with equine asthma, in contrast to healthy control horses,
did not react to antigenic challenge with a significant
upregulation of the FoxP3 expression in the BAL.32 This
can possibly be ascribed to the fact that the reactive
capacity of Tregs in equine asthma is generally dimin-
ished.32 In the comparison of treatments, there were no
statistically significant differences in the FoxP3 expres-
sion, although the beclomethasone group showed an
increase after 8 weeks and the CpGsd showed a decrease.
Certain reasons indicate that FoxP3 is not the ideal
marker to analyze the activity of Tregs. Since the
transcription factor for humans is described as a marker
for nonactivated regulatory T cells,71 it is possible that
FoxP3 in horses is also more likely a measured value for
nonactivated, rather than activated Tregs.
In an in vitro study of horses with insect bite
hypersensitivity (IBH), the FoxP3 expression in those
horses was significantly lower after antigen stimulation
than in healthy horses.72 Since IBH, like equine asthma,
is a disease with an allergic genesis, this suggests that
horses with equine asthma also have a diminished ability
to produce Tregs. This would explain the absence of an
increase in the CpG groups. However, the beclometha-
sone group did show an increase after 8 weeks.
A study by Robbin et al determined that even healthy
horses over 15 years old display a significantly lower
percentage of FoxP3 positive CD4+ cells than younger
horses.60 Therefore, one may assume that the immunological
reaction of the Tregs in the horses examined was additionally
reduced due to their ages. Older humans suffering from
asthma also display a lower FoxP3 mRNA expression.73
Since the determination of Tregs ideally requires the
evaluation of a combination of FoxP3 and the marker
CD25 from CD4+ T cells, and not FoxP3 alone, a FACS
analysis is better suited to make a statement on the
activity of Tregs than the mRNA determination.
The regulatory function of Tregs is mediated by the
cytokine TGF‐β, in addition to IL‐10 and others.62 The
potential to influence numerous immunological reactions
is attributed to this cytokine, including a direct anti‐
inflammatory effect on Th1 cells as well as an influence
on healing processes and fibrosis of tissue.74
The TGF‐β‐mRNA expression of CD4+ cells was
measured via real‐time PCR. Here, there was no
significant change of the TGF‐β‐mRNA expression at II
or III for any of the three treatment groups. A study from
Desjardins et al74 was also unable to determine differ-
ences in the TGF‐β concentration after allergenic
challenge in the BAL of healthy horses or horses with
equine asthma. These results indicate that TGF‐β does
not play a great role in the pathophysiology of equine
asthma.74 In human asthma, a connection could be made
between an increased expression of TGF‐β and the
reconstruction of the lungs in a bronchial fibrosis,75
although this could not yet be confirmed in horses.74
The transcription factor T‐bet could have great signifi-
cance for the mediation of the effect of the CpG, since its
activation promotes Th1‐associated cytokines and simulta-
neously inhibits Th2 associated cytokines.76 T‐bet is con-
sidered in human medicine to be a “fate‐deciding” factor for
a Th1 immune response,77 and in this is significantly
influenced by the cytokines IL‐4 and IFN‐γ. It can be
considered the counterpart to the transcription factor
GATA‐3, since this factor is influenced by the same cytokines
and can induce a Th2‐dominated immune response when
activated.77 In addition, it influences both the acquired
immune system, as well as the innate immune system.78 The
CpGsd showed a reduction of the T‐bet expression after 8
weeks. In connection with the decrease in IFN‐γ, IL‐4 and
GATA‐3, this is also considered a positive balancing
immunomodulatory effect in the CpGsd group, in which
neither Th1 nor Th2 dominates. One must consider the
results for T‐bet in this relationship in the context of the
results for the Th2 cytokine IL‐4. Here, both the beclo-
methasone group and the CpGsd group could achieve a
significant reduction of the IL‐4 concentration directly after
treatment, analogous to the results of a study by Giguere, in
which an inhalative fluticasone therapy also effected a
decrease in the allergy‐mediating Th2 cytokine.54
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The slight change in the expression of the transcrip-
tion factor T‐bet, with the exception of the CpGsd group,
could also be the result of a deficit of T‐bet in horses
suffering from equine asthma over a long period of time,
as described by Vale‐Pereira et al73 in human long‐term
sufferers of asthma.
In human asthma, a significant role of the transcription
factor GATA‐3 was determined for a Th2‐dominated
phenotype.79 Therefore, GATA‐3 has already been eval-
uated as a target protein in asthma therapy for humans.79
An increase from GATA‐3, as in the beclomethasone
group after 8 weeks, would therefore be considered
unfavourable for the progression of the disease. In
contrast, the CpG group showed a decrease. However, a
study by Couetil et al80 could not determine any difference
in the GATA‐3 activity between healthy horses and horses
with equine asthma.
The minor change in the GATA‐3 expression could be
associated with the ages of the study's subjects and their
resulting immunosenescence, or the age‐related de-
creased efficiency of the immune systems, which has
been especially detected in the lungs.73,81
The mRNA expression of the IL‐8 cytokine, which serves
as an inflammatory mediator and plays a particular role in
the chemotactic recruitment of neutrophils,54 was signifi-
cantly reduced in both CpG groups after 8 weeks. A part of
the effect of corticosteroids is generally attributed to their
inhibitive influence on the expression of IL‐8, amongst
others.66 This observation was not made in this study.
In a study by Giguere et al54 a positive correlation
between the IL‐8 concentration and the percentage of
neutrophils could be established. Similar results could be
achieved in both CpG groups, which showed a significant
decrease in IL‐8 after 8 weeks. The neutrophilic granulo-
cytes also sank significantly after treatment, and this effect
was also sustained after 8 weeks. Thus, the therapy
achieved an anti‐inflammatory effect, which is one of the
most important goals in the therapy for equine asthma.
The summarizing analysis of all clinical results directly
after the last inhalation determined that the CpGsd
resulted in a significant improvement in 82% of the
parameters, while the CpGdd therapy had a significant,
positive effect on 72% of the parameters. The corticosteroid
treatment with beclomethasone also showed a significant
improvement in 72% of the clinical parameters.
In the long‐term evaluation, the CpGsd showed a
significant, sustained improvement in 100% of the para-
meters in comparison to the initial values, while the
CpGdd showed a significant improvement in 67%, and the
corticosteroid therapy in only 50% of the parameters.
In comparison to the preceding studies considering
the long‐term effect, the current study reveals that 10
inhalations resulted in medium to high clinical effects on
100% of the parameters upon 8 weeks after the final
treatment (Table S5). Seven inhalations22 showed middle
to high clinical effects on 80% of the measured values
upon 6 weeks after treatment. In the study, in which the
patients received five CpG inhalations,16 middle to high
clinical effects were measured in 50% of the parameters 4
weeks after the final treatment. These results indicate
that more frequent inhalations work effectively over a
longer period of time (8 weeks).
Through the reduction of their symptoms with the
CpG therapy, the horses return to a higher performance
potential, and can even be trained more intensively and
used for riding, which was often not possible before the
therapy, due to the associated limitations of the disease.
Particularly striking is the indication that the inhalation
with CpG‐GNP, especially considering the sustained
therapeutic effect, has an advantage over the corticoster-
oid therapy. With a longer sustained effect, the intervals
between treatments could be extended.
The interpretation of the cytokine results is difficult, since
the individual values can vary greatly among different
horses.30,81 An evaluation of repeated boosters could reveal
more, for example after 3 to 4 weeks or as needed dependent
on symptoms. Repeated stimulation of the immune system
with CpG could enhance the immunomodulatory effect
through the induction of IL‐10.67 This could lead to the
creation of memory cells, which could result in a stronger
immune response upon renewed contact.66
This therapy concept could also be relevant for other
allergic diseases, such as IBH and multiple hypersensi-
tivities.82,83
Equine asthma is a naturally occurring animal model
for human allergic neutrophilic asthma.6 Therefore, the
application and evaluation of this immunomodulatory
inhalative treatment is of great interest for human
allergic asthma, and could establish a new treatment
option beyond solely symptomatic treatment.
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